financetom
Business
financetom
/
Business
/
Abercrombie & Fitch Fiscal Q2 Adjusted Earnings Fall, Net Sales Increase; Adjusts Full-Year Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Abercrombie & Fitch Fiscal Q2 Adjusted Earnings Fall, Net Sales Increase; Adjusts Full-Year Guidance
Aug 27, 2025 5:25 AM

08:04 AM EDT, 08/27/2025 (MT Newswires) -- Abercrombie & Fitch ( ANF ) reported fiscal Q2 adjusted earnings Wednesday of $2.32 per diluted share, down from $2.50 a year earlier.

Analysts polled by FactSet expected $2.30.

Net sales for the fiscal quarter ended Aug. 2 were $1.21 billion, compared with $1.13 billion a year earlier.

Analysts surveyed by FactSet expected $1.20 billion.

For fiscal Q3, the company expects net income in the range of $2.05 to $2.25 per share. Analysts polled by FactSet expect $2.51.

The company projects fiscal Q3 net sales growth of 5% to 7%. Analysts surveyed by FactSet expect net sales of $1.26 billion.

For the full year, Abercrombie & Fitch ( ANF ) anticipates net income in the range of $10 to $10.50, compared with its prior outlook of $9.50 to $10.50. Analysts polled by FactSet expect $10.14.

The company expects full-year net sales growth of 5% to 7%. It had previously expected 3% to 6% growth. Analysts surveyed by FactSet expect net sales of $5.21 billion.

Shares of the company were down 0.6% in recent Wednesday premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Roche to acquire US-based Poseida Therapeutics
Roche to acquire US-based Poseida Therapeutics
Nov 25, 2024
BERLIN, Nov 26 (Reuters) - Roche will acquire California-based biopharmafirm Poseida Therapeutics ( PSTX ) for $9 per share at closing, for a total equity value of $1 billion, the Swiss company said on Tuesday. Stockholders will also receive a non-tradeable contingent value right (CVR) for $4 per share, representing a total deal value of up to approximately $1.5 billion,...
Roche to acquire US firm Poseida Therapeutics in $1.5 billion deal
Roche to acquire US firm Poseida Therapeutics in $1.5 billion deal
Nov 25, 2024
ZURICH (Reuters) -Switzerland's Roche will acquire U.S. biopharma firm Poseida Therapeutics ( PSTX ) in a cash deal worth up to $1.5 billion, the companies said on Tuesday. Poseida is to be bought at $9 per share in cash, and stockholders will also receive a non-tradeable contingent value right for up to $4 per share if specific milestones are met,...
Disney settles suit over women's pay for $43 million
Disney settles suit over women's pay for $43 million
Nov 25, 2024
Nov 26 (Reuters) - Walt Disney ( DIS ) has agreed to pay $43.3 million to settle a lawsuit alleging that its female employees in California earned $150 million less than their male counterparts over an eight-year period, the plaintiffs' lawyers said in a statement on Monday. As part of the settlement, Disney ( DIS ) has agreed to retain...
Walmart to roll back some diversity policies amid pressure from conservatives
Walmart to roll back some diversity policies amid pressure from conservatives
Nov 25, 2024
Nov 26 (Reuters) - Walmart ( WMT ) plans to cut back some of its diversity, equity and inclusion (DEI) initiatives, a spokesperson for the retailer said on Monday, joining a growing list of firms feeling the heat from conservative groups. Bloomberg News reported that Walmart ( WMT ) will no longer consider race and gender to boost diversity when...
Copyright 2023-2026 - www.financetom.com All Rights Reserved